Leadership Overview
Teva has 10 executives leading key functions including financial strategy, commercial excellence, corporate development, and global operations.
Focused on advancing global health outcomes, Teva delivers a diverse portfolio of complex generics and innovative therapies to address unmet patient needs through scientific research and streamlined treatment delivery.
Focused on advancing global health outcomes, Teva delivers a diverse portfolio of complex generics and innovative therapies to address unmet patient needs through scientific research and streamlined treatment delivery.
Leadership Roles at Teva
Marija Bubanja - Chief Financial Officer
Marija Bubanja, the Chief Financial Officer at Teva, directs the global financial architecture and capital allocation strategies. Bubanja oversees fiscal reporting, risk management, and long-term investment planning to ensure the sustainability of the biopharmaceutical portfolio. By aligning financial resources with research and development goals, the Chief Financial Officer supports the expansion of generic and innovative medicine access. This leadership role involves rigorous oversight of budgetary compliance and the optimization of cost structures across international markets. Marija Bubanja maintains close collaboration with the executive board to drive shareholder value and operational efficiency. Through precise financial modeling and data-driven forecasting, the Chief Financial Officer strengthens the market position of the organization. Ultimately, Bubanja secures the necessary capital to fuel the development of cutting-edge therapeutic solutions for patients worldwide.
Luigi Tiravanti - Director, Finance & Chief Financial Officer
Luigi Tiravanti, the Director, Finance & Chief Financial Officer at Teva, manages regional financial operations and internal audit protocols. Tiravanti architects robust financial frameworks to support the manufacturing and distribution of complex generics. Overseeing the integration of financial data into operational workflows, the Director, Finance & Chief Financial Officer ensures transparency and regulatory adherence across all business units. This role involves analyzing market trends to mitigate economic risks while maximizing profitability within the pharmaceutical sector. Luigi Tiravanti coordinates with cross-functional teams to streamline the delivery of medicines and improve health outcomes. By implementing advanced accounting standards and fiscal controls, the Director, Finance & Chief Financial Officer maintains the integrity of the corporate balance sheet. Ultimately, Tiravanti drives financial stability to support the broader mission of expanding access to quality healthcare treatments.
Craig Olson - Global Chief Financial Officer, Operations
Craig Olson, the Global Chief Financial Officer, Operations at Teva, manages the financial health of the manufacturing and supply chain divisions. Olson oversees cost-efficiency programs and capital expenditure projects that support the production of high-quality medicines. By monitoring the financial performance of global production facilities, the Global Chief Financial Officer, Operations ensures that the supply chain remains resilient and responsive to patient needs. This role involves analyzing production costs and optimizing inventory management to reduce waste and improve margins. Craig Olson coordinates with operational leaders to align financial targets with manufacturing output. Through rigorous financial oversight and process improvement, the Global Chief Financial Officer, Operations supports the scalability of the generics business. Ultimately, Olson ensures that the operational infrastructure remains financially sound to deliver life-saving treatments to patients across the globe.
Efrat Yehudai - Senior Vice President, Chief Financial Officer ) Teva Global Operations( ( Tech Operations)
Efrat Yehudai, the Senior Vice President, Chief Financial Officer ) Teva Global Operations( ( Tech Operations) at Teva, directs the financial strategy for the technology and operational infrastructure. Yehudai oversees the investment in digital transformation and manufacturing technology to enhance production capabilities. By managing the budget for technical operations, the Senior Vice President, Chief Financial Officer ) Teva Global Operations( ( Tech Operations) ensures that the company leverages cutting-edge tools to streamline medicine delivery. This role involves evaluating the return on investment for new technologies and optimizing the cost of technical services. Efrat Yehudai collaborates with engineering and IT teams to align financial resources with innovation goals. Through strategic financial planning, the Senior Vice President, Chief Financial Officer ) Teva Global Operations( ( Tech Operations) supports the modernization of the global supply chain. Ultimately, Yehudai drives operational excellence through technology-focused financial management.
Eli Kalif - Chief Financial Officer & Executive VP
Eli Kalif, the Chief Financial Officer & Executive VP at Teva, leads the overall financial strategy and corporate governance for the global enterprise. Kalif oversees the capital structure, investor relations, and long-term financial planning to support the mission of improving patient health outcomes. By directing the financial operations of the entire organization, the Chief Financial Officer & Executive VP ensures that resources are allocated to high-impact research and development projects. This leadership role involves managing relationships with financial institutions and ensuring compliance with global regulatory standards. Eli Kalif collaborates with the executive team to drive sustainable growth and operational efficiency. Through strategic oversight of the balance sheet and cash flow, the Chief Financial Officer & Executive VP maintains the financial health of the company. Ultimately, Kalif provides the fiscal foundation necessary to deliver a broad portfolio of medicines to patients worldwide.
Dov Primovitch - Chief Financial Officer (Israel)
Dov Primovitch, the Chief Financial Officer (Israel) at Teva, manages the financial operations and fiscal reporting for the domestic market. Primovitch oversees local budgetary compliance and tax planning to support the manufacturing and research activities based in the region. By ensuring the financial stability of the local business unit, the Chief Financial Officer (Israel) enables the continuous production of essential medicines. This role involves coordinating with local leadership to align financial performance with the broader corporate objectives. Dov Primovitch monitors economic conditions and regulatory changes to mitigate risks within the domestic market. Through precise financial management and reporting, the Chief Financial Officer (Israel) supports the operational efficiency of the local facilities. Ultimately, Primovitch ensures that the regional financial infrastructure remains robust to support the global mission of expanding access to quality healthcare treatments.
Nishank Bhargava - Regional Director, Finance & Chief Financial Officer (India)
Nishank Bhargava, the Regional Director, Finance & Chief Financial Officer (India) at Teva, directs the financial strategy for the Indian operations. Bhargava oversees the fiscal management of manufacturing sites and research centers to ensure cost-effective production of generics. By managing local financial risks and regulatory requirements, the Regional Director, Finance & Chief Financial Officer (India) supports the expansion of the company footprint in the region. This role involves optimizing the supply chain costs and ensuring that financial resources are available for local innovation. Nishank Bhargava collaborates with regional teams to align financial performance with global operational standards. Through rigorous financial oversight and strategic planning, the Regional Director, Finance & Chief Financial Officer (India) drives the efficiency of the Indian business unit. Ultimately, Bhargava secures the financial resources needed to deliver high-quality medicines to patients in the region and beyond.
Guillermo Monroy - LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy)
Guillermo Monroy, the LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy) at Teva, executes growth initiatives across the Latin American market. Monroy identifies strategic acquisition targets and partnership opportunities to bolster the regional portfolio of biosimilars and pharmacy brands. Overseeing the execution of complex mergers, the LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy) ensures seamless integration of new assets into the existing business model. This leadership role involves conducting deep-dive market analysis to identify gaps in patient care and therapeutic availability. Guillermo Monroy collaborates with regional leadership to align corporate strategy with local healthcare demands. By fostering strategic alliances and optimizing the product pipeline, the LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy) accelerates market penetration. Ultimately, Monroy expands the footprint of the company within the competitive pharmaceutical landscape.
Martin Laughlin - Chief of Staff and Head of Commercial Excellence
Martin Laughlin, the Chief of Staff and Head of Commercial Excellence at Teva, drives the optimization of sales processes and marketing effectiveness. Laughlin oversees the implementation of commercial strategies that enhance the reach of innovative therapies and established generics. By refining the go-to-market approach, the Chief of Staff and Head of Commercial Excellence ensures that healthcare providers receive timely access to essential medicines. This role involves coordinating cross-departmental efforts to improve customer engagement and brand performance. Martin Laughlin analyzes performance metrics to identify areas for operational improvement and revenue growth. Through the deployment of advanced analytics and sales force training, the Chief of Staff and Head of Commercial Excellence elevates the standard of service delivery. Ultimately, Laughlin supports the organizational goal of improving patient health outcomes by maximizing the impact of the commercial portfolio.
Hagay Leibowitz - Chief Marketing Officer, Project & Tgo, Teva Leader
Hagay Leibowitz, the Chief Marketing Officer, Project & Tgo, Teva Leader at Teva, directs the global branding and product positioning for the diverse medicine portfolio. Leibowitz oversees the strategic launch of new therapeutic solutions and manages the lifecycle of existing pharmacy brands. By crafting compelling value propositions, the Chief Marketing Officer, Project & Tgo, Teva Leader ensures that the company remains a preferred partner for healthcare systems and patients. This leadership role involves managing complex projects that integrate marketing efforts with global operations to streamline treatment delivery. Hagay Leibowitz collaborates with research teams to translate scientific advancements into market-ready products. Through innovative digital campaigns and stakeholder engagement, the Chief Marketing Officer, Project & Tgo, Teva Leader drives brand awareness and market share. Ultimately, Leibowitz strengthens the reputation of the organization as a leader in the biopharmaceutical industry.
Explore Leadership Teams in Manufacturing
Founded in 1954 and headquartered in Suresnes, France, Servier international is an independent pharmaceutical company governed by a non-profit foundation. Their three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in their production centres around the world.
Company Leadership DM
KP
FG
Sandoz Group AG (SIX: SDZ) is a global healthcare company focused on developing, manufacturing, and delivering high-quality generic medicines and biosimilars. Serving patients worldwide, Sandoz provides treatments across multiple therapeutic areas, including oncology, immunology, and cardiovascular health.
Company Leadership SS
MF
BP
EM
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. PPS also offers development and manufacturing services for biologics including vaccines, gene therapies, and monoclonal antibodies, made possible through Piramal Pharma Limited's investment in Yapan Bio Private Limited. Our track record as a trusted service provider with experience across varied technologies we believe makes us a partner of choice for innovator and generic companies worldwide.
Company Leadership SL
BC
RM
As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.
Company Leadership DM
EM
BP
SK
Frequently Asked Questions Regarding Teva Top Executives and Leadership Team
